A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk (original) (raw)

References

  1. American Diabetes Association. Standards of medical care in diabetes–2008. Diabetes Care 31 (Suppl. 1), S12–S54 (2008).
  2. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20, 1183–1197 (1997).
  3. Tirosh, A. et al. Normal fasting plasma glucose levels and type 2 diabetes in young men. N. Engl. J. Med. 353, 1454–1462 (2005).
    Article CAS PubMed Google Scholar
  4. Barr, E.L. et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation 116, 151–157 (2007).
    Article CAS PubMed Google Scholar
  5. Bouatia-Naji, N. et al. A polymorphism within the G6PC2 gene is associated with fasting plasma glucose levels. Science 320, 1085–1088 (2008).
    Article CAS PubMed Google Scholar
  6. Peschke, E. Melatonin, endocrine pancreas and diabetes. J. Pineal Res. 44, 26–40 (2008).
    CAS PubMed Google Scholar
  7. Van Cauter, E. Putative roles of melatonin in glucose regulation. Therapie 53, 467–472 (1998).
    CAS PubMed Google Scholar
  8. Boden, G., Ruiz, J., Urbain, J.L. & Chen, X. Evidence for a circadian rhythm of insulin secretion. Am. J. Physiol. 271, E246–E252 (1996).
    CAS PubMed Google Scholar
  9. Peschke, E. et al. Diabetic Goto Kakizaki rats as well as type 2 diabetic patients show a decreased diurnal serum melatonin level and an increased pancreatic melatonin-receptor status. J. Pineal Res. 40, 135–143 (2006).
    Article CAS PubMed Google Scholar
  10. Ramracheya, R.D. et al. Function and expression of melatonin receptors on human pancreatic islets. J. Pineal Res. 44, 273–279 (2008).
    Article CAS PubMed Google Scholar
  11. Dixon, A.L. et al. A genome-wide association study of global gene expression. Nat. Genet. 39, 1202–1207 (2007).
    Article CAS PubMed Google Scholar
  12. Myers, A.J. et al. A survey of genetic human cortical gene expression. Nat. Genet. 39, 1494–1499 (2007).
    Article CAS PubMed Google Scholar
  13. Sladek, R. et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 445, 881–885 (2007).
    Article CAS PubMed Google Scholar
  14. Balkau, B. An epidemiologic survey from a network of French Health Examination Centres, (D.E.S.I.R.): epidemiologic data on the insulin resistance syndrome. Rev. Epidemiol. Sante Publique 44, 373–375 (1996).
    CAS PubMed Google Scholar
  15. Visvikis-Siest, S. & Siest, G. The STANISLAS Cohort: a 10-year follow-up of supposed healthy families. Gene-environment interactions, reference values and evaluation of biomarkers in prevention of cardiovascular diseases. Clin. Chem. Lab. Med. 46, 733–747 (2008).
    Article CAS PubMed Google Scholar
  16. Heude, B. et al. Anthropometric relationships between parents and children throughout childhood: the Fleurbaix-Laventie Ville Sante Study. Int. J. Obes. (Lond) 29, 1222–1229 (2005).
    Article CAS Google Scholar
  17. Hinds, D.A. et al. Whole-genome patterns of common DNA variation in three human populations. Science 307, 1072–1079 (2005).
    Article CAS PubMed Google Scholar
  18. Pritchard, J.K., Stephens, M. & Donnelly, P. Inference of population structure using multilocus genotype data. Genetics 155, 945–959 (2000).
    CAS PubMed PubMed Central Google Scholar
  19. Matthews, D.R. et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412–419 (1985).
    Article CAS PubMed Google Scholar
  20. Jorgensen, T. et al. A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: baseline results Inter99. Eur. J. Cardiovasc. Prev. Rehabil. 10, 377–386 (2003).
    Article PubMed Google Scholar
  21. Wallace, T.M., Levy, J.C. & Matthews, D.R. Use and abuse of HOMA modeling. Diabetes Care 27, 1487–1495 (2004).
    Article PubMed Google Scholar
  22. Jarvelin, M.R. et al. Ecological and individual predictors of birthweight in a northern Finland birth cohort 1986. Paediatr. Perinat. Epidemiol. 11, 298–312 (1997).
    Article CAS PubMed Google Scholar
  23. Jaquet, D., Collin, D., Levy-Marchal, C. & Czernichow, P. Adult height distribution in subjects born small for gestational age. Horm. Res. 62, 92–96 (2004).
    CAS PubMed Google Scholar
  24. Hadjadj, S. et al. Prognostic value of the insertion/deletion polymorphism of the ACE gene in type 2 diabetic subjects: results from the Non-insulin-dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR), Diabete de type 2, Nephropathie et Genetique (DIAB2NEPHROGENE), and Survie, Diabete de type 2 et Genetique (SURDIAGENE) studies. Diabetes Care 31, 1847–1852 (2008).
    Article CAS PubMed PubMed Central Google Scholar
  25. Lukowiak, B. et al. Identification and purification of functional human beta-cells by a new specific zinc-fluorescent probe. J. Histochem. Cytochem. 49, 519–528 (2001).
    Article CAS PubMed Google Scholar
  26. Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81, 559–575 (2007).
    Article CAS PubMed PubMed Central Google Scholar
  27. Burton, P.R. et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat. Genet. 39, 1329–1337 (2007).
    Article CAS PubMed Google Scholar
  28. Marchini, J., Howie, B., Myers, S., McVean, G. & Donnelly, P. A new multipoint method for genome-wide association studies by imputation of genotypes. Nat. Genet. 39, 906–913 (2007).
    Article CAS PubMed Google Scholar

Download references

Acknowledgements

The study was supported in part by an ALFEDIAM-Les laboratoires Servier grant, the “Conseil Regional Nord-Pas-de-Calais: Fonds européen de développement économique et regional,” Genome Quebec-Genome Canada and the British Medical Research Council. N.B.-N.'s position is supported by a grant from the ANR (Agence Nationale pour la Recherche: ANR-06 PHYSIO - 037 -02). A.B. is funded by a research fellowship from the French nonprofit “Association pour l'Etude des Anomalies Congénitales.” We acknowledge funding to P.F. by the European Union (Integrated Project EURODIA LSHM-CT-2006-518153 in the Framework Programme 6 [FP06] of the European-Community). We thank M. Deweirder and F. Allegaert for DNA extraction of part of the cohorts studied; S. Gaget and S. Gallina for bioinformatics support; S. Poulain and P. Gallina for the recruitment of obese children families; B. Guardiola-Lemaitre for fruitful discussion on results; and C. Lecoeur for statistical assistance. We acknowledge the “Centre de Médecine Préventive (CMP) de Vandoeuvre-Les-Nancy” where the STANISLAS cohort was recruited. The DESIR study has been supported by INSERM, CNAMTS, Lilly, Novartis Pharma and Sanofi-Aventis, the Association Diabète Risque Vasculaire, the Fédération Française de Cardiologie, La Fondation de France, ALFEDIAM, ONIVINS, Ardix Medical, Bayer Diagnostics, Becton Dickinson, Cardionics, Merck Santé, Novo Nordisk, Pierre Fabre, Roche and Topcon. The Diab-2-Néphrogène/Surdiagène study acknowledges the participating patients, physicians and the staff of the CIC Poitiers, PHRC (Projet Hospitalier de Recherche Clinique), and a 2003-AFD-grant. The NFBC86 is supported by the European Commission; contract number QLG1-CT-2000-01643, Biocenter, University of Oulu, Finland and the Academy of Finland. We thank L. Peltonen for providing NFBC86 DNA samples. The Inter99 study was supported by grants from the Lundbeck Foundation Centre of Applied Medical Genomics for Personalized Disease Prediction, Prevention and Care (LUCAMP), the Danish Medical Research Council, Novo Nordisk, the FOOD Study Group/the Danish Ministry of Food, Agriculture and Fisheries, the Danish Diabetes Association and the European Union (EUGENE2, grant no. LSHM-CT-2004-512013), and from the Swedish Research Council (J.H.).

Author information

Author notes

  1. Nabila Bouatia-Naji and Amélie Bonnefond: These authors equally contributed to this work.

Authors and Affiliations

  1. CNRS-UMR-8090, Institute of Biology and Lille 2 University, Pasteur Institute, Lille, F-59019, France
    Nabila Bouatia-Naji, Amélie Bonnefond, Christine Cavalcanti-Proença, Marion Marchand, Jérôme Delplanque, Stéphane Lobbens, Emmanuelle Durand, Franck De Graeve, Jean-Claude Chèvre, Stéphane Cauchi, Martine Vaxillaire, David Meyre, Christian Dina & Philippe Froguel
  2. Steno Diabetes Center, Niels Steensens Vej 1, NLC2.13, Gentofte, DK-2820, Denmark
    Thomas Sparsø, Johan Holmkvist, Knut Borch-Johnsen, Torben Hansen & Oluf Pedersen
  3. Department of Human Genetics, Faculty of Medicine, McGill University, Montreal, H3H 1P3, Canada
    Ghislain Rocheleau & Robert Sladek
  4. Genome Quebec Innovation Centre, Montreal, H3A 1A4, Canada
    Ghislain Rocheleau & Robert Sladek
  5. Prognomix, Montreal, H1Y 3L1, Canada
    Ghislain Rocheleau
  6. Faculty of Health Science, University of Aarhus, Aarhus C, DK-8000, Denmark
    Knut Borch-Johnsen & Oluf Pedersen
  7. Department of Clinical Sciences/ Obstetrics and Gynecology, University of Oulu, FIN-, 90014, Finland
    Anna-Liisa Hartikainen
  8. Department of Clinical Sciences/ Clinical Chemistry, University of Oulu, FIN- 90014 University of Oulu, Finland
    Aimo Ruokonen
  9. Institut inter-régional pour la santé (IRSA), F-37521, La Riche, France
    Jean Tichet
  10. Department of Endocrinology, Diabetology and Nutrition, Bichat-Claude Bernard University Hospital, Assistance Publique des Hôpitaux de Paris, Paris, F-75018, France
    Michel Marre
  11. INSERM U695, Université Paris 7, Paris, F-75870, France
    Michel Marre
  12. Pediatric Endocrine Unit, Jeanne de Flandre Hospital, Lille, F-59800, France
    Jacques Weill
  13. INSERM U780, Villejuif, F-94807; University Paris-Sud, Orsay, F-91405, France
    Barbara Heude & Beverley Balkau
  14. INSERM U563, Children's Hospital, CHU, Toulouse, F-31059, France
    Maithé Tauber
  15. Department Molecular Cell Biology Katholieke Universiteit, Gene Expression unit, Leuven, B-3000, Belgium
    Katleen Lemaire & Frans Schuit
  16. Department of Epidemiology and Public Health, Imperial College London, London, W2 1PG, UK
    Paul Elliott & Marjo-Riita Jarvelin
  17. Research Centre for Prevention and Health, Glostrup University Hospital, DK-2600, Denmark
    Torben Jørgensen
  18. Faculty of Health Science, University of Copenhagen, Copenhagen, DK-2200, Denmark
    Torben Jørgensen & Oluf Pedersen
  19. Endocrinology-Diabetology Unit, Corbeil-Essonnes Hospital, Essonnes, F-91108, France
    Guillaume Charpentier
  20. Centre hospitalier universitaire de Poitiers, Endocrinologie Diabetologie, CIC INSERM 0802, INSERM U927, Université de Poitiers, UFR Médecine Pharmacie, Poitiers, F-86034, France
    Samy Hadjadj
  21. INSERM “Cardiovascular Genetics” team, CIC 9501, Nancy, F-54000, France
    Sophie Visvikis-Siest
  22. INSERM, Unité 690, Robert Debré hospital, Paris, F- 75019, France, Paris Diderot University, Paris, F-75005, France
    Claire Lévy-Marchal
  23. INSERM U859, CHRU de Lille, Université Lille-Nord de France, Lille, F-59045, France
    François Pattou
  24. Genomic Medicine, Hammersmith Hospital, Imperial College London, London, W12 0NN, UK
    Alexandra I F Blakemore, Andrew J Walley & Philippe Froguel
  25. Department of Child and Adolescent Health, Institute of Health Sciences, University of Oulu, Finland, National Public Health Institute, Finland, Biocenter Oulu, University of Oulu, FIN-, Oulu, 90014, Finland
    Marjo-Riita Jarvelin
  26. Faculty of Health Science, University of Southern, Denmark, DK-5230, Odense, Denmark
    Torben Hansen

Authors

  1. Nabila Bouatia-Naji
  2. Amélie Bonnefond
  3. Christine Cavalcanti-Proença
  4. Thomas Sparsø
  5. Johan Holmkvist
  6. Marion Marchand
  7. Jérôme Delplanque
  8. Stéphane Lobbens
  9. Ghislain Rocheleau
  10. Emmanuelle Durand
  11. Franck De Graeve
  12. Jean-Claude Chèvre
  13. Knut Borch-Johnsen
  14. Anna-Liisa Hartikainen
  15. Aimo Ruokonen
  16. Jean Tichet
  17. Michel Marre
  18. Jacques Weill
  19. Barbara Heude
  20. Maithé Tauber
  21. Katleen Lemaire
  22. Frans Schuit
  23. Paul Elliott
  24. Torben Jørgensen
  25. Guillaume Charpentier
  26. Samy Hadjadj
  27. Stéphane Cauchi
  28. Martine Vaxillaire
  29. Robert Sladek
  30. Sophie Visvikis-Siest
  31. Beverley Balkau
  32. Claire Lévy-Marchal
  33. François Pattou
  34. David Meyre
  35. Alexandra I F Blakemore
  36. Marjo-Riita Jarvelin
  37. Andrew J Walley
  38. Torben Hansen
  39. Christian Dina
  40. Oluf Pedersen
  41. Philippe Froguel

Contributions

N.B.-N. was responsible for the design and data analyses, the study follow-up and the manuscript writing. A.B. was responsible for and performed the gene expression study and was involved in the genotyping of the replication stage, the gene sequencing and the manuscript writing. C.C.-P. performed the statistical analysis in the French and Finnish populations and was involved in the manuscript writing. T.S. and J.H. performed statistical analysis in the Danish samples and were involved in the manuscript writing. M. Marchand was involved in the genotyping of the replication stage, gene expression and gene sequencing. J.D. supervised the genotyping of the GWA data. S.L. and E.D. performed the GWA genotyping. G.R. and R.S. were involved in the type 2 diabetes and obesity GWA studies and the manuscript writing. F.D.G. was involved in the bioinformatics analyses for the GWA studies and the in silico eQTL analyses. J.-C.C. performed the in silico eQTL analyses. K.B.-J., A.-L.H., A.R., J.T., M. Marre, J.W., B.H., M.T., P.E., T.J., G.C., S.H., S.V.-S. and C.L.-M. provided DNA samples and phenotype data. B.B. and M.-R.J. provided DNA samples and phenotype data and were involved in the manuscript writing. T.H. and O.P. provided access to DNA samples and phenotype data, supervised the genotyping and the statistical analyses in the Danish samples and were involved in the manuscript writing. D.M. supervised the obesity GWA study. S.C. and M.V. were involved in the manuscript writing. F.P. provided the human pancreatic islets and sorted beta cells. K.L. and F.S. provided expression data in the mouse. A.I.F.B. and A.J.W. were involved in the obesity GWA study and the manuscript writing. C.D. was involved in the study design and the manuscript writing and supervised the statistical analyses. P.F. was the principal investigator of the study and was involved in the study design and the manuscript writing. All authors approved the data and the final manuscript.

Corresponding author

Correspondence toPhilippe Froguel.

Supplementary information

Rights and permissions

About this article

Cite this article

Bouatia-Naji, N., Bonnefond, A., Cavalcanti-Proença, C. et al. A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk.Nat Genet 41, 89–94 (2009). https://doi.org/10.1038/ng.277

Download citation